Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

115.86 -0.35 (-0.30%)

Streaming Delayed Price Updated: 1:56 PM EDT, Mar 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Biotech Stocks Take Another Beating As 'Chaos' Reigns At FDA With Reports Of Mass Firings ↗

April 01, 2025

Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles.

Via Investor's Business Daily

Topics Workforce

MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline

April 01, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24

April 01, 2025

From Merck & Co., Inc.

Via Business Wire

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol? ↗

March 31, 2025

The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.

Via Investor's Business Daily

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial

March 31, 2025

From Merck Sharp & Dohme

Via Business Wire

Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades. ↗

March 31, 2025

Via The Motley Fool

Topics Intellectual Property Retirement

ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

March 30, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

March 30, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

What's going on in today's session: S&P500 movers ↗

March 28, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Which S&P500 stocks are moving on Friday? ↗

March 28, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Which Dow Jones Stock Is Cheaper, Amgen or Merck? ↗

March 28, 2025

Via The Motley Fool

Topics Intellectual Property Stocks

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

March 27, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial

March 27, 2025

From Merck & Co., Inc.

Via Business Wire

Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares? ↗

March 27, 2025

The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.

Via Investor's Business Daily

Is Merck Stock a Bargain Buy? ↗

March 27, 2025

Via The Motley Fool

Faruqi & Faruqi Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK

March 26, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK

March 26, 2025

From Pomerantz LLP

Via GlobeNewswire

European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

March 26, 2025

From Merck & Co., Inc.

Via Business Wire

Gamestop, FST Corp, Merck, UPS, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

March 25, 2025

The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at 18,271.86, while the Dow remained largely flat at 42,587.50. The S&P 500 edged...

Via Benzinga

Topics Stocks

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm

March 25, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗

March 25, 2025

Via The Motley Fool

What's going on in today's session: S&P500 movers ↗

March 25, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Via Chartmill

Tuesday's session: top gainers and losers in the S&P500 index ↗

March 25, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Via Chartmill

Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed ↗

March 25, 2025

The Chinese company will receive $200 million upfront and will be eligible to earn up to $1.77 billion in milestone payments and royalties on net sales of the drug, if approved.

Via Stocktwits

Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment ↗

March 25, 2025

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

Via Benzinga

Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges ↗

March 25, 2025

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.

Via Benzinga

Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.

March 25, 2025

From Merck & Co., Inc.

Via Business Wire

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics ↗

March 24, 2025

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.

Via Benzinga

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

March 24, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.